Филипини - Енглески - FDA (Food And Drug Administration)

s.m.h.p. marketing & consultancy; distributor: s.m.h.p. marketing & consultancy - pyrazinamide - tablet - 500mg

Сингапур - Енглески - HSA (Health Sciences Authority)

sunward pharmaceutical private limited - pyrazinamide - tablet - 500 mg - pyrazinamide 500 mg

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

major pharmaceuticals - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease contr

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

remedyrepack inc. - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendation of cdc. it is possible these patients may require a longer course of treatment). it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease control (cdc) and american thoracic society for complete regimen and dosage recommendations. 4 pyrazinamide is contraindicated in persons: - with severe hepatic damage. - who have shown hypersensitivity to it. - with acute gout.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

novitium pharma llc - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for disease contr

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

remedyrepack inc. - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (the current recommendation of the cdc for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (patients with drug-resistant disease should be treated with regimens individualized to their situation. pyrazinamide frequently will be an important component of such therapy.) (in patients with concomitant hiv infection, the physician should be aware of current recommendations of cdc. it is possible these patients may require a longer course of treatment.) it is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. pyrazinamide should only be used in conjunction with other effective antituberculous agents. *see recommendations of center for

Малта - Енглески - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - pyrazinamide - tablet - pyrazinamide 500 mg - antimycobacterials

Малта - Енглески - Medicines Authority

morningside healthcare limited unit c, harcourt way, leicester, le19 1wp, united kingdom - pyrazinamide - tablet - pyrazinamide 500 mg - antimycobacterials

Арменија - Енглески - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

macleods pharmaceuticals ltd. - pyrazinamide - tablets - 400mg

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

remedyrepack inc. - pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - pyrazinamide 500 mg